Similarly, a third-generation CAR targeting epidermal growth factor receptor (EGFR) in NK-92 cells, combined with the kinase inhibitor cabozantinib, effectively lysed EGFR-positive renal cell carcinoma (RCC) cells and improved tumour homing (166). The gene discussed is EGFR; the disease is renal cell carcinoma.